SCHEMBL4479104

SCHEMBL4479104

Cc1ccc(C(=O)c2ccc(C)cc2C2CCCCC2=O)c(C2CCCCC2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
GAA P10253 2/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
HSD17B2 P37059 2/20 0.36
LMNA P02545 2/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MCL1 Q07820 1/20 0.36
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B1 P14061 1/20 0.34
TLR4 O00206 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617366 0.84 NPC1 (0.38) NPC1RAB9AGAAPTGDR2SIRT1
SCHEMBL30496227 0.84 NPC1 (0.38) NPC1RAB9AGAAPTGDR2SIRT1
SCHEMBL27652147 0.76 PTGDR2 (0.55) NPC1RAB9AGAAPTGDR2HSD17B2
SCHEMBL27430751 0.75 PTGDR2 (0.43) NPC1RAB9AGAAPTGDR2LMNA
SCHEMBL3662535 0.74 MAOA (0.33) NPC1RAB9AGAASIRT1KMT2A
SCHEMBL27436953 0.74 PTGDR2 (0.44) NPC1RAB9APTGDR2HSD17B2LMNA
SCHEMBL5254475 0.73 UGT2B17 (0.38) NPC1RAB9ASIRT1LMNASMN1; SMN2
SCHEMBL24815345 0.71 DDB1 (0.53) MCL1KMT2ATLR4USP2ALDH1A1
SCHEMBL29973239 0.71 DDB1 (0.53) MCL1KMT2ATLR4USP2ALDH1A1
SCHEMBL15874850 0.71 DDB1 (0.53) MCL1KMT2ATLR4USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR NPC1 3239/4885RAB9A 3692/4885GAA 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.